Related Experiment Video
Updated: Oct 9, 2025

Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound 30/45MHZ System
Published on: May 5, 2018
Smoking influence on early and late fetal growth
Beatriz Fernandez-Rodriguez1, Ana Roche Gomez2, Blanca Sofia Jimenez Moreno2
1Department of Pediatrics, University Hospital Del Tajo, Aranjuez, Madrid, Spain.
Insights
Smoking during pregnancy is linked to fetal growth restriction (FGR) and low birthweight after 34 weeks. This study found no significant association in earlier deliveries, highlighting a critical gestational window for intervention.
Area of Science:
- Obstetrics and Gynecology
- Perinatal Medicine
- Maternal-Fetal Medicine
Background:
- Smoking during pregnancy is a significant, modifiable risk factor for adverse fetal outcomes.
- Fetal growth restriction (FGR) and low birthweight are leading causes of neonatal morbidity and mortality.
- Understanding the impact of maternal smoking on fetal development across gestation is crucial.
Purpose of the Study:
- To investigate the association between maternal smoking and the development of early (<34 weeks) and late (>34 weeks) fetal growth restriction (FGR) or low birthweight.
- To examine the effects of smoking on uteroplacental and fetoplacental hemodynamics in growth-restricted fetuses.
Main Methods:
- Retrospective cohort study of 5,537 singleton pregnancies.
- Pregnancies categorized into early (<34 weeks) and late (>34 weeks) delivery groups.
- FGR diagnosed using customized fetal growth standards and fetal Doppler; birthweight assessed with the Olsen newborn chart.
Main Results:
- In late deliveries (>34 weeks), smoking was significantly associated with FGR (5% vs 1.3%, p<0.001) and lower birthweights (<3rd and <10th centiles).
- Late FGR in smokers showed higher umbilical artery Doppler resistances.
- No significant association between smoking and FGR, birthweight, or hemodynamics was found in early deliveries (<34 weeks).
Conclusions:
- Maternal smoking is associated with increased risk of FGR, low birthweight, and altered fetal hemodynamics after 34 weeks gestation.
- The detrimental effects of smoking on fetal growth appear more pronounced in later stages of pregnancy.
- Interventions to reduce smoking during pregnancy may be particularly impactful for preventing late-onset FGR.
Objectives:
Smoking during pregnancy is a leading and modifiable risk factor for fetal growth restriction (FGR) and low birthweight (<10th centile). We studied the effects of smoking in the development of early and late FGR or low birthweight, as well as in uteroplacental and fetoplacental hemodynamics of growth-restricted fetuses.
Methods:
Retrospective cohort study of 5,537 consecutive singleton pregnancies delivered at ≤34 + 0 ("early delivery" group, n=95) and >34 + 0 ("late delivery" group, n=5,442) weeks of gestation. Each group was divided into smokers and non-smokers. Prenatal diagnosis of FGR was based on customized fetal growth standards and fetal Doppler, and postnatal birthweight was assessed using the Olsen newborn chart.
Results:
There were 15/95 (15.8%) and 602/5,442 (11.1%) smokers in the early and late delivery groups, respectively. In early deliveries, FGR was diagnosed in 3/15 (20%) of smokers and in 20/80 (25%) of non-smokers (p=0.68). We also found no differences in birthweights and hemodynamics. In late deliveres, FGR was detected in 30/602 (5%) smokers and 64/4,840 (1.3%) non-smokers (p<0.001). Birthweights <3rd centile and <10th centile were more common in smokers vs. non-smokers: 38/602 (6.3%) vs. 87/4,840 (1.8%) and 89/602 (14.8%) vs. 288/4,840 (6%), respectively (all p<0.01). Fetal Doppler of late FGR showed slightly higher umbilical artery resistances in smokers.
Conclusions:
Smoking in pregnancy is associated with FGR, low birthweight and higher umbilical artery Doppler resistances after 34 weeks of gestation, but we could not confirm this association in earlier deliveries.
Related Concept Videos
Stress Prevention and Stress Management Techniques IV
Statistical Methods for Analyzing Epidemiological Data
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Teratogenicity

